Company news
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) news
Bluejay Diagnostics, Inc. news releases on 6ix. Latest, Sep 8, 2026: Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access…
Press releases & updates
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
September 8, 2026
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
August 13, 2026
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
July 21, 2026
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
June 4, 2026
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 2, 2026
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
June 2, 2026
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
May 7, 2026
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
April 6, 2026
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
March 12, 2026
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
March 5, 2026
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
February 20, 2026
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
February 17, 2026
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
January 27, 2026
Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production
December 29, 2025
Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships
November 10, 2025
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market under Nasdaq Rules
October 13, 2025
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
October 10, 2025
Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
October 9, 2025
Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform
October 9, 2025
Bluejay Diagnostics Provides Second Quarter Business and Corporate Update
August 7, 2025
Bluejay Diagnostics Provides Mid-Year Business and Corporate Update
June 3, 2025
Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting
April 15, 2025
Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds
April 7, 2025
Bluejay Diagnostics : Announces Reverse Stock Split Form 8 K
November 18, 2024
Bluejay Diagnostics Announces Reverse Stock Split
November 12, 2024
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
June 27, 2024
Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering
June 26, 2024
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
January 1, 2024
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
December 27, 2023
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
December 26, 2023
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
November 8, 2023
Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
August 24, 2023
Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results
August 15, 2023
Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 9, 2023
Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy
May 18, 2023
Bluejay Diagnostics Reports First Quarter 2023 Financial Results
May 9, 2023
Bluejay Diagnostics Reports 2022 Financial Results
March 19, 2023
Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America
February 15, 2023
Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results
November 8, 2022
Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
July 25, 2022
Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test
July 5, 2022
Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test
June 8, 2022
Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results
April 19, 2022
Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance
March 27, 2022
Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer
March 23, 2022
Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 9, 2022
Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA
January 30, 2022
Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care
January 12, 2022
Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor
January 4, 2022
Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results
December 15, 2021